SK472004A3 - Purification and crystalline forms of zaleplon - Google Patents

Purification and crystalline forms of zaleplon Download PDF

Info

Publication number
SK472004A3
SK472004A3 SK47-2004A SK472004A SK472004A3 SK 472004 A3 SK472004 A3 SK 472004A3 SK 472004 A SK472004 A SK 472004A SK 472004 A3 SK472004 A3 SK 472004A3
Authority
SK
Slovakia
Prior art keywords
zaleplon
solution
water
organic solvent
solvent
Prior art date
Application number
SK47-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Erika Feher
Ferenc Korodi
Claude Singer
Erika Magyar
Original Assignee
Biogal Gyogyszergyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/170,673 external-priority patent/US6884888B2/en
Application filed by Biogal Gyogyszergyar filed Critical Biogal Gyogyszergyar
Publication of SK472004A3 publication Critical patent/SK472004A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555Hetero-N
    • Y10T436/147777Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK47-2004A 2001-08-01 2002-08-01 Purification and crystalline forms of zaleplon SK472004A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30939101P 2001-08-01 2001-08-01
US31790701P 2001-09-06 2001-09-06
US38819902P 2002-06-12 2002-06-12
US10/170,673 US6884888B2 (en) 2001-06-12 2002-06-12 Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)
PCT/US2002/024553 WO2003011228A2 (fr) 2001-08-01 2002-08-01 Procede de purification de n-[3-(3-cyanopyrazolo[1,5-a]pyrimidine-7-yl)phenyl]-n-ethylacetamide(zaleplon) et des formes cristallines de zaleplon auxquelles ce procede donne acces

Publications (1)

Publication Number Publication Date
SK472004A3 true SK472004A3 (en) 2004-12-01

Family

ID=27496922

Family Applications (1)

Application Number Title Priority Date Filing Date
SK47-2004A SK472004A3 (en) 2001-08-01 2002-08-01 Purification and crystalline forms of zaleplon

Country Status (14)

Country Link
US (2) US6852858B2 (fr)
EP (1) EP1430054A4 (fr)
JP (1) JP2005523874A (fr)
CA (1) CA2453751A1 (fr)
CZ (1) CZ200471A3 (fr)
HR (1) HRP20040180A2 (fr)
HU (1) HUP0402253A3 (fr)
IL (1) IL160076A0 (fr)
IS (1) IS7128A (fr)
MX (1) MXPA04001035A (fr)
NO (1) NO20040887L (fr)
PL (1) PL374176A1 (fr)
SK (1) SK472004A3 (fr)
WO (1) WO2003011228A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL365678A1 (en) * 2000-08-03 2005-01-10 Wyeth Polymorphs of zaleplon and methods for the preparation thereof
HUP0402257A2 (hu) * 2001-06-12 2005-02-28 BIOGAL Gyógyszergyár Rt. Eljárás az N-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)-fenil]-N-etil-acetamid (zaleplon) előállítására
US20050032818A1 (en) * 2001-06-12 2005-02-10 Entire Interest N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethylacetamide and crystalline forms of zaleplon
CA2453751A1 (fr) * 2001-08-01 2003-02-13 Biogal Gyogyszergyar Rt. Procede de purification de n-[3-(3-cyanopyrazolo[1,5-a]pyrimidine-7-yl)phenyl]-n-ethylacetamide(zaleplon) et des formes cristallines de zaleplon auxquelles ce procede donne acces
KR20040086375A (ko) * 2002-02-15 2004-10-08 비오갈 기오기스제르갸르 알티. 소정의 입도 분포를 갖는 잘레플론을 포함하는 분말조성물 및 이로부터 생성된 약학적 생성물
CZ20023575A3 (cs) * 2002-10-25 2004-01-14 Léčiva, A.S. Způsob výroby N-ethyl-N-[3-(3-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-fenyl]-acetamidu (zaleplonu)
WO2005023813A1 (fr) 2003-09-04 2005-03-17 Cipla Limited Synthese du zaleplon
CN1906197A (zh) * 2004-01-14 2007-01-31 马林克罗特公司 用于合成选择的吡唑并嘧啶的两相方法
HUP0400325A3 (en) * 2004-02-02 2005-11-28 Richter Gedeon Vegyeszet Pure n-[3-(-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethyl-acetamide, process for its preparation and intermediates
EP1837343A4 (fr) * 2004-12-08 2009-07-29 Kuraray Co Procédé servant à produire du benzoate de (5 alpha, 7 alpha)-3-spiro-2'-(1',3'-dioxolan)-24-oxocholest-22-èn-7-yle
WO2007043939A1 (fr) * 2005-10-07 2007-04-19 Astrazeneca Ab Nouvelle forme cristalline de 3,5-dibromo-n-[(2s)-2-(4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-1-yl)butyl]-n-methylbenzamide, modification a
US7761955B1 (en) * 2007-08-30 2010-07-27 Hiltz Erik D Dual port cleaning and extraction apparatus
US8171598B1 (en) 2010-07-26 2012-05-08 Erik Daniel Hiltz Dual port cleaning and extraction apparatus
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626538A (en) 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US5714607A (en) 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
DE10004790B4 (de) 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
WO2001078725A2 (fr) 2000-04-13 2001-10-25 Synthon B.V. Formulations a liberation modifiee contenant un agent hypnotique
PL365678A1 (en) * 2000-08-03 2005-01-10 Wyeth Polymorphs of zaleplon and methods for the preparation thereof
AR029780A1 (es) * 2000-12-13 2003-07-16 Gador Sa Procedimiento mejorado para la obtencion de n-[3(3-ciano-pirazolo[1,5-a]pirimidin-7-il)fenil]-n-etil-acetamida
HUP0402257A2 (hu) * 2001-06-12 2005-02-28 BIOGAL Gyógyszergyár Rt. Eljárás az N-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)-fenil]-N-etil-acetamid (zaleplon) előállítására
CA2453751A1 (fr) * 2001-08-01 2003-02-13 Biogal Gyogyszergyar Rt. Procede de purification de n-[3-(3-cyanopyrazolo[1,5-a]pyrimidine-7-yl)phenyl]-n-ethylacetamide(zaleplon) et des formes cristallines de zaleplon auxquelles ce procede donne acces
US7034155B2 (en) * 2002-02-14 2006-04-25 Cilag Ag Method for producing n-ethyl-n-[3-(3-cyanopyrazolo[1,5a]pyrimidine-7-yl)phenyl]acetamide
PL207322B1 (pl) 2002-05-14 2010-11-30 Adamed Społka Z Ograniczoną Odpowiedzialnością Sposób wytwarzania zaleplonu
CZ20023575A3 (cs) * 2002-10-25 2004-01-14 Léčiva, A.S. Způsob výroby N-ethyl-N-[3-(3-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-fenyl]-acetamidu (zaleplonu)

Also Published As

Publication number Publication date
PL374176A1 (en) 2005-10-03
HRP20040180A2 (en) 2004-12-31
IS7128A (is) 2004-01-28
CZ200471A3 (cs) 2004-11-10
NO20040887L (no) 2004-02-27
IL160076A0 (en) 2004-06-20
HUP0402253A2 (hu) 2005-02-28
EP1430054A4 (fr) 2005-06-22
US7348429B2 (en) 2008-03-25
WO2003011228A3 (fr) 2003-10-30
CA2453751A1 (fr) 2003-02-13
JP2005523874A (ja) 2005-08-11
US6852858B2 (en) 2005-02-08
EP1430054A2 (fr) 2004-06-23
US20050065168A1 (en) 2005-03-24
WO2003011228A2 (fr) 2003-02-13
HUP0402253A3 (en) 2005-12-28
MXPA04001035A (es) 2004-06-22
US20030130291A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
US20200390768A1 (en) Salt of fused heterocyclic derivative and crystal thereof
US7439373B2 (en) Crystalline mycophenolate sodium
SK472004A3 (en) Purification and crystalline forms of zaleplon
US6903106B2 (en) Polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US20090076272A1 (en) Polymorphs of eszopiclone malate
US20080015197A1 (en) Process for the preparatrion of zopiclone
EP1507531B1 (fr) Compositions pharmaceutiques stables de desloratadine
US7776852B2 (en) Process for producing highly pure midazolam and salts thereof
US20120283274A1 (en) Crystalline forms of substituted pyrazolopyrimidines
CN115160186B (zh) 氨基甲酸苯酯晶型及其制备方法
US11434226B2 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
RU2727974C2 (ru) Соли 1-(4-(2-((1-(3,4-дифторфенил)-1н-пиразол-3-ил)метокси)этил)пиперазин-1-ил)этанона
US20050032818A1 (en) N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethylacetamide and crystalline forms of zaleplon
US20070238739A1 (en) Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon) and crystalline forms of zaleplon accessible with the process
KR100909923B1 (ko) N-(2,3-디메틸-5,6,7,8-테트라히드로푸로[2,3-b]퀴놀린-4-일)-2-(2-옥소피롤리딘-1-일)아세트아미드의 다형체
ZA200400378B (en) Purification and crystalline forms of zaleplon
EP0066762B1 (fr) Dérivés de la 1,7-dihydropyrrolo(3,4-e)(1,4)diazépin-2(1H)one
EP1768969B1 (fr) Mycophenolate de sodium cristallin
WO2019086008A1 (fr) Forme cristalline de dérivé de benzotriazole et procédé de préparation et utilisation associés
AU2002329687A1 (en) Purification and crystalline forms of zaleplon
US20070191425A1 (en) Solifenacin-containing composition
CN117377658A (zh) 喹啉衍生物化合物的制备方法
KR20110028320A (ko) 가바펜틴 에나카르빌 염 및 이의 제조 방법

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure